User:Eelerne/CD4 immunoadhesin/Bibliography

Structure and function section:


 * Barbas CF, Björling E, Chiodi F, Dunlop N, Cababa D, Jones TM, Zebedee SL, Persson MA, Nara PL, Norrby E. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro Proceedings of the National Academy of Sciences of the United States of America. January 1992.


 * Orentas RJ, Hildreth JE. Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV AIDS Research and Human Retroviruses. August 1993.
 * Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, Byrn R. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection Journal of Immunology. February 1991.
 * Schols D, Struyf S, Van Damme J, Este JA, Henson G, De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4 Journal of Experimental Medicine. July 1997.
 * Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Günthard HF. Delay of HIV-1 rebound after cessation of antiretroviral

Clinical application section:


 * Dimitrov DS. Therapeutic proteins Methods in Molecular Biology. 2012.
 * Markowitz M, Ho DD. Antiretroviral therapy and drug resistance Seminars in HIV/AIDS. July 2003.
 * Mascola JR, Louder MK, VanCott TC, Sapan CV, Lambert JS, Muenz LR, Bunow B, Birx DL, Robb ML. Two antigenicity-scaffold molecules that reflect disparate biases in breadth and specificity Human Antibodies and Hybridomas. 1997.
 * NIAID News Release: NIH Study Finds CD4 Immunoadhesin Safe in HIV-Infected People. National Institute of Allergy and Infectious Diseases. October 14, 1999.
 * Ketas TJ, Klasse PJ, Spenlehauer C, Nesin M, Frank I, Pope M, Strizki J, Zolla-Pazner S, Moore JP. Entry inhibitors that bind the CD4 receptor and prevent HIV-1 entry Recent Patents on Anti-Infective Drug Discovery. January 2006.
 * Root MJ, Kay MS, Kim PS. Protein design of an HIV-1 entry inhibitor Science. May 2001.
 * Thomas D, Klibanov OM, Conry-Cantilena C, Skurnick J, Zolla-Pazner S. Clinical development of CD4-immunoglobulin G2 for treatment of human immunodeficiency virus infection Clinical and Diagnostic Laboratory Immunology. September 1997.

History and significance:


 * Dimitrov DS. Therapeutic proteins Methods in Molecular Biology. 2012.
 * Mascola JR, Louder MK, VanCott TC, Sapan CV, Lambert JS, Muenz LR, Bunow B, Birx DL, Robb ML. Two antigenicity-scaffold molecules that reflect disparate biases in breadth and specificity Human Antibodies and Hybridomas. 1997.
 * Ketas TJ, Klasse PJ, Spenlehauer C, Nesin M, Frank I, Pope M, Strizki J, Zolla-Pazner S, Moore JP. Entry inhibitors that bind the CD4 receptor and prevent HIV-1 entry Recent Patents on Anti-Infective Drug Discovery. January 2006.
 * Root MJ, Kay MS, Kim PS. Protein design of an HIV-1 entry inhibitor Science. May 2001.
 * Thomas D, Klibanov OM, Conry-Cantilena C, Skurnick J, Zolla-Pazner S. Clinical development of CD4-immunoglobulin G2 for treatment of human immunodeficiency virus infection Clinical and Diagnostic Laboratory Immunology. September 1997.

Classification section


 * Posner MR, Cavacini LA, Emes CL, Power J, Byrn R. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120 Journal of Acquired Immune Deficiency Syndromes. 1993.
 * Smith JA, Daniel R. Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway Journal of Virology. May 2006.
 * Vázquez-Salat N, Yélamos J, Pedraza MA, Falo C, Jiménez-Barbero J, Martín-Lomas M. Engineering of the N-terminal region of CD4: a stable immunoadhesin with superagonist activity European Journal of Immunology. February 2004.
 * Presta LG. Engineering of therapeutic immunoglobulin Fc fragments: exploiting a novel repertoire of biological effector functions Experimental Opinion on Biological Therapy. November 2008.
 * Lozano F, Shen L, Peña J, Ho WY, Gasser RA, Kalvatchev Z, Hixon J, Fung M, Chiu M, Liu J, Wong-Staal F, Broder CC. Resistance to diverse HIV-1 fusion inhibitors conferred by distinct mutations in the viral envelope glycoprotein and the CD4 receptor protein Molecular Therapy. November 2012.

Future uses section:

References:


 * 1) Fätkenheuer G, Pozniak A, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11(11):1170-2.
 * 2) Khalili K, Del Valle L, Muralidharan A, et al. Antiviral effect of human immunodeficiency virus type 1 tat on viral replication. J Virol. 2003;77(17):9533-40.
 * 3) Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29-37.
 * 4) Canete JD, Pablos JL, Sanmarti R, et al. Anti-inflammatory effects of abatacept in rheumatoid arthritis synovial membrane tissue. Ann Rheum Dis. 2006;65(7):896-902.
 * 5) Gaidot A, Landry C